High Growth Tech Stocks To Watch In December 2024

Simply Wall St.12-21

Over the last 7 days, the United States market has dropped 3.5%, yet it remains up by 22% over the past year with earnings forecasted to grow by 15% annually. In this context, identifying high growth ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2493342762?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/IO2v6Az9Ftp5BwGxWk_U3A--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8dd43bf33c3f09b3bd16e76b99877c31","is_english":true,"pubTime":"2024-12-21 02:02","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2493342762","market":"us","top_or_hot":-1,"title":"High Growth Tech Stocks To Watch In December 2024","media":"Simply Wall St.","content":"<div>\n<p>Over the last 7 days, the United States market has dropped 3.5%, yet it remains up by 22% over the past year with earnings forecasted to grow by 15% annually. In this context, identifying high growth ...</p>\n\n<a href=\"https://finance.yahoo.com/news/high-growth-tech-stocks-watch-180251644.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>High Growth Tech Stocks To Watch In December 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHigh Growth Tech Stocks To Watch In December 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-21 02:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/high-growth-tech-stocks-watch-180251644.html><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Over the last 7 days, the United States market has dropped 3.5%, yet it remains up by 22% over the past year with earnings forecasted to grow by 15% annually. In this context, identifying high growth ...</p>\n\n<a href=\"https://finance.yahoo.com/news/high-growth-tech-stocks-watch-180251644.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://finance.yahoo.com/news/high-growth-tech-stocks-watch-180251644.html","article_id":"2493342762","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/IO2v6Az9Ftp5BwGxWk_U3A--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8dd43bf33c3f09b3bd16e76b99877c31"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2493342762","pubTimestamp":1734717771,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Over the last 7 days, the United States market has dropped 3.5%, yet it remains up by 22% over the past year with earnings forecasted to grow by 15% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these positive earnings forecasts despite recent market volatility.Top 10 High Growth Tech Companies In The United States. Take a closer look at Akebia Therapeutics' potential here in our health report.Examine Akebia Therapeutics' past performance report to understand how it has performed in the past.Aldeyra Therapeutics has demonstrated a robust commitment to innovation in the biotech sector, particu","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AKBA":"Akebia Therapeutics, Inc.","ALDX":"Aldeyra Therapeutics Inc","INFN":"英飞朗"},"translate_title":"2024年12月值得关注的高增长科技股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKBA":0.9,"ALDX":0.9,"INFN":0.9},"content_text":"Over the last 7 days, the United States market has dropped 3.5%, yet it remains up by 22% over the past year with earnings forecasted to grow by 15% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these positive earnings forecasts despite recent market volatility.\nTop 10 High Growth Tech Companies In The United States\n\n\n\nName\nRevenue Growth\nEarnings Growth\nGrowth Rating\n\n\nSuper Micro Computer\n23.95%\n24.32%\n★★★★★★\n\n\nArdelyx\n25.47%\n69.63%\n★★★★★★\n\n\nSarepta Therapeutics\n23.98%\n42.48%\n★★★★★★\n\n\nAlnylam Pharmaceuticals\n22.34%\n70.30%\n★★★★★★\n\n\nClene\n77.61%\n59.19%\n★★★★★★\n\n\nTG Therapeutics\n34.86%\n56.98%\n★★★★★★\n\n\nAlkami Technology\n21.99%\n102.65%\n★★★★★★\n\n\nTravere Therapeutics\n31.70%\n72.51%\n★★★★★★\n\n\nSeagen\n22.57%\n71.80%\n★★★★★★\n\n\nImmunoGen\n26.00%\n45.85%\n★★★★★★\n\n\n\nClick here to see the full list of 237 stocks from our US High Growth Tech and AI Stocks screener.\nLet's explore several standout options from the results in the screener.\nAkebia Therapeutics\nSimply Wall St Growth Rating: ★★★★★☆\nOverview: Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutics for kidney disease patients, with a market cap of approximately $384 million.\nOperations: Akebia Therapeutics generates revenue primarily from developing and commercializing novel therapeutics for kidney disease, amounting to $169.88 million.\nAkebia Therapeutics, despite being unprofitable, shows promise with a forecasted annual revenue growth of 27.1%, significantly outpacing the US market's 9.1%. This growth is underpinned by its recent FDA approval of Vafseo for treating anemia in dialysis patients, a significant milestone expected to drive future revenues upon its January 2025 launch. The company's strategic engagement at key healthcare conferences and the initiation of the VOICE trial underscore its commitment to solidifying Vafseo’s market position. However, challenges remain with a net loss widening this quarter compared to last year, emphasizing the need for careful monitoring of its financial health as it scales operations.\n\nTake a closer look at Akebia Therapeutics' potential here in our health report.\nExamine Akebia Therapeutics' past performance report to understand how it has performed in the past.\n\n\n\n\n  NasdaqCM:AKBA Earnings and Revenue Growth as at Dec 2024\n \n\nAldeyra Therapeutics\nSimply Wall St Growth Rating: ★★★★★☆\nOverview: Aldeyra Therapeutics, Inc. is a biotechnology company focused on developing and commercializing medicines for immune-mediated diseases, with a market cap of $290.60 million.\nOperations: Aldeyra Therapeutics specializes in creating and marketing treatments for immune-mediated diseases. With a market capitalization of approximately $290.60 million, the company is positioned within the biotechnology sector.\nAldeyra Therapeutics has demonstrated a robust commitment to innovation in the biotech sector, particularly with its recent advancements in dry eye disease treatments. The company's resubmission of a New Drug Application for reproxalap shows promise, supported by statistically significant trial results that position it favorably for FDA approval. Despite widening net losses reported in Q3 2024, Aldeyra's strategic presentations at key healthcare conferences and its extended debt financing terms suggest a calculated approach to sustaining operations while pursuing growth. With an expected revenue surge of 55.5% annually, significantly outstripping the US market average of 9.1%, and projected earnings growth of 71.6% per year, Aldeyra is navigating its challenges with strategic initiatives that could reshape its financial landscape and bolster its market presence in upcoming years.\n\nUnlock comprehensive insights into our analysis of Aldeyra Therapeutics stock in this health report.\nExplore historical data to track Aldeyra Therapeutics' performance over time in our Past section.\n\n\n\n\n  NasdaqCM:ALDX Earnings and Revenue Growth as at Dec 2024\n \n\nInfinera\nSimply Wall St Growth Rating: ★★★★★☆\nOverview: Infinera Corporation manufactures semiconductors and supplies networking equipment, optical semiconductors, software, and services globally with a market capitalization of approximately $1.56 billion.\nOperations: The company generates its revenue primarily from the sale of optical transport networking equipment, software, and related services, amounting to $1.46 billion.\nInfinera, amid a challenging fiscal period with a reported revenue decrease to $354.4 million in Q3 2024 from $392.37 million the previous year, continues to innovate in high-capacity optical networks. Despite its current unprofitability and a net loss increase to $124 million over nine months, the company is poised for recovery with strategic client engagements like Converge ICT Solutions for the Bifrost Cable System and Poka Lambro's regional network upgrade in Texas. These partnerships leverage Infinera’s advanced ICE7 technology, enhancing long-distance data transmission capabilities and supporting substantial infrastructure projects. This positions Infinera uniquely within tech sectors reliant on robust data handling capacities, forecasting an annual revenue growth of 9.7%, potentially outpacing the broader US market's growth rate of 9.1%.\n\nClick to explore a detailed breakdown of our findings in Infinera's health report.\nUnderstand Infinera's track record by examining our Past report.\n\n\n\n\n  NasdaqGS:INFN Earnings and Revenue Growth as at Dec 2024\n \n\nTaking Advantage\n\nTake a closer look at our US High Growth Tech and AI Stocks list of 237 companies by clicking here.\nAre you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.\nDiscover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.\n\nReady To Venture Into Other Investment Styles?\n\nExplore high-performing small cap companies that haven't yet garnered significant analyst attention.\nFuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.\nFind companies with promising cash flow potential yet trading below their fair value.\n\n This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.\nCompanies discussed in this article include NasdaqCM:AKBA NasdaqCM:ALDX and NasdaqGS:INFN.\nHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2493342762"}